caveat emptor
For those who are looking at MBP for the first time, I would remind you that its anti-obesity product AOD9604 has NOT yet been proven to reduce weight in humans.
Earlier trials have shown that AOD9604 has an optimum dosage, above which its efficacy in metabolizing fat actually DECREASES.
If the optimum dosage proves not to be sufficient to cause significant weight loss, MBP will be a near WORTHLESS stock as virtually all of its value is tied up in the potential of AOD9604.
If the efficacy trials about to get under way do show significant weight loss, then holders will be laughing. But if you can't afford to lose the money, don't hold this stock because failure in the upcoming efficacy trials will cause the share price to implode.
MBP Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held
